- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 1, 2024
Distillery Therapeutics
Targeting an ALKBH5-IL11 receptor axis for cardiac fibrosis
BioCentury | Aug 26, 2022
Discovery & Translation
Detecting Parkinson’s via breathing signals; plus Antisense, Noster and more
BioCentury’s roundup of translational news
BioCentury | Mar 4, 2022
Distillery Therapeutics
Oral allosteric modulator of NPR1 for cardiovascular disease
BioCentury | Jan 3, 2022
Product Development
What’s next for voltage-gated sodium channel blockers
Companies dial in subtype selectivity, explore new modalities, and move to more homogeneous trial populations
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Dec 12, 2018
Preclinical News
Repurposing hypertension drugs to block cytokine release syndrome
BioCentury | Nov 16, 2015
Regulation
Scaling compassion
FDA, industry, patient groups charting compassionate use policies
Items per page:
1 - 10 of 534